Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

GYRE Relative to the S&P 500

GYRE Relative to the Sector

Seasonal Chart Analysis

Analysis of the Gyre Therapeutics, Inc. (NASD:GYRE) seasonal charts above shows that a Buy Date of June 27 and a Sell Date of September 15 has resulted in a geometric average return of 7.71% above the benchmark rate of the S&P 500 Total Return Index over the past 18 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 18 years by an average of 38.89% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

To download GYRE seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: GYRE